Mashoudy Kayla D, Ye-Tay Joselyn, Nouri Keyvan
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1150 NW 14th Street, Miami, FL, 33136, USA.
Department of Pediatrics, Nicklaus Children's Hospital, 3100 SW 62nd Ave, Miami, FL, 33155, USA.
Arch Dermatol Res. 2025 Jan 13;317(1):231. doi: 10.1007/s00403-024-03763-x.
Pityriasis rosea (PR) is an acute exanthematous disease with an uncertain physiopathology, increasingly recognized as potentially drug induced. This study aims to investigate medication triggers associated with PR by analyzing cases reported in the FDA Adverse Event Reporting System (FAERS) database. A retrospective review of 343 PR cases reported in the FAERS database from January 1, 1998, to March 31, 2024, was conducted. Reporting odds ratios (ROR) were calculated to assess associations between PR and specific drug classes, including tumor necrosis factor (TNF) inhibitors and angiotensin-converting enzyme (ACE) inhibitors. Logistic regression analysis evaluated the influence of factors such as sex, age group, and seriousness of outcomes on the occurrence of PR. Females represented 56.3% of cases and the 18-64 age group comprised 55.4% of cases. TNF inhibitors were significantly associated with PR (ROR = 4.1881 [3.1970-5.4865], P < 0.0001), particularly infliximab (ROR = 6.5284 [3.9523-10.7837], P < 0.0001), etanercept (ROR = 3.4921 [2.2873-5.3315], P < 0.0001), and adalimumab (ROR = 3.086 [2.0213-4.7115], P < 0.0001). ACE inhibitors were also associated with PR (ROR = 9.9808 [6.0423-16.4864], P < 0.0001), with higher odds in older patients (OR 14.08 [4.2-47.2], P < 0.0001) and those reporting serious outcomes (OR 9.53 [1.24-72.99], P = 0.03). Based on the FAERS, there has been a consistent rise in PR cases, with TNF inhibitors and ACE inhibitors being associated medication classes tied to PR. Given the limited literature on drug-related triggers and patient demographics, we aimed to highlight the characteristics of PR cases that could enhance awareness and inform better clinical outcomes for affected patients.
玫瑰糠疹（PR）是一种急性发疹性疾病，其生理病理学尚不明确，越来越被认为可能是药物诱发的。本研究旨在通过分析美国食品药品监督管理局不良事件报告系统（FAERS）数据库中报告的病例，调查与PR相关的药物触发因素。对1998年1月1日至2024年3月31日期间FAERS数据库中报告的343例PR病例进行了回顾性研究。计算报告比值比（ROR）以评估PR与特定药物类别之间的关联，包括肿瘤坏死因子（TNF）抑制剂和血管紧张素转换酶（ACE）抑制剂。逻辑回归分析评估了性别、年龄组和结局严重程度等因素对PR发生的影响。女性占病例的56.3%，18 - 64岁年龄组占病例的55.4%。TNF抑制剂与PR显著相关（ROR = 4.1881 [3.1970 - 5.4865]，P < 0.0001），尤其是英夫利昔单抗（ROR = 6.5284 [3.9523 - 10.7837]，P < 0.0001）、依那西普（ROR = 3.4921 [2.2873 - 5.3315]，P < 0.0001）和阿达木单抗（ROR = 3.086 [2.0213 - 4.7115]，P < 0.0001）。ACE抑制剂也与PR相关（ROR = 9.9808 [6.0423 - 16.4864]，P < 0.0001），老年患者（OR 14.08 [4.2 - 47.2]，P < 0.0001）和报告严重结局的患者（OR 9.53 [1.24 - 72.99]，P = 0.03）的关联几率更高。基于FAERS，PR病例呈持续上升趋势，TNF抑制剂和ACE抑制剂是与PR相关的药物类别。鉴于关于药物相关触发因素和患者人口统计学的文献有限，我们旨在突出PR病例的特征，以提高认识并为受影响患者带来更好的临床结局。
